BioRx and BioDx: Can the Two Businesses Mix?
Executive Summary
Few biotech companies venture into diagnostics, largely because they believe that therapeutics and diagnostics don’t mix. However, a handful of biotech/ small pharmaceutical companies are active in diagnostics and therapeutics, taking largely one of two approaches: using diagnostics to obtain near-term cash flow or as an integral part of a broader strategy in disease management.
You may also be interested in...
Do Dx-Life Science Synergies Exist? Beckman Says 'You Bet They Do'
Life sciences and clinical diagnostics seem to have a lot in common, but their customer needs, margins and product life cycles differ significantly. Beckman Coulter, one of the few large diagnostics companies with significant life science commitments, argues vociferously in favor of the strategic value of leveraging both businesses, despite many difficulties. Its MHC tetramer program is a prime example of its strategy.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.